AUTHOR=Meng Kehui , Xiang Heng , Wu Meiyu , Xie Ouyang , Li Andong , Tan Chongqing , Wan Xiaomin 

TITLE=Evaluating nivolumab plus gemcitabine–cisplatin’s cost-effectiveness for aUC in China

JOURNAL=Frontiers in Pharmacology

VOLUME=15

YEAR=2024

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1382342

DOI=10.3389/fphar.2024.1382342

ISSN=1663-9812

ABSTRACT=<sec><title>Aims</title><p>Assessing the cost-effectiveness of Nivolumab with Gemcitabine–Cisplatin for Advanced Urothelial Carcinoma (aUC) treatment from the perspective of Chinese payers.</p></sec><sec><title>Methods</title><p>A Markov model assessed economic outcomes, estimating health outcomes in quality-adjusted life years (QALYs). One-way and probabilistic sensitivity analyses were conducted to assess the impact of uncertainties on the results.</p></sec><sec><title>Results</title><p>The base-case analysis showed Nivolumab plus Gemcitabine–Cisplatin yielded 0.59 QALYs at an extra cost of $78,780.61, leading to an incremental cost-effectiveness ratios (ICER) of $133,526.46/QALY. One-way sensitivity analysis highlighted Nivolumab’s cost as the key factor, while probabilistic sensitivity analysis showed a 0% chance of cost-effectiveness for Nivolumab plus Gemcitabine–Cisplatin in aUC treatment.</p></sec><sec><title>Conclusion</title><p>Nivolumab plus Gemcitabine–Cisplatin is not cost-effective in the treatment of aUC.</p></sec>